Stay updated with breaking news from Advicenne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Advicenne agreement further validates Avanzanite's unique business model and establishes it as the go-to commercialization partner for medicines treating rare diseases across Europe Avanzanite
Sibnayal® will now be available in four of the five major European markets Significant expansion of commercial opportunities for Sibnayal® (potassium citrate/ potassium bicarbonate) Regulatory
Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-out Sustained growth in the number of patients with access to Sibnayal® in Europe Regulatory
Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-out Sustained growth in the number of patients with access to Sibnayal® in Europe Regulatory
Sales of Sibnayal® reached 1.4 million euros, a significant increase of 40% over one year Significant growth acceleration in H2 2022 Regulatory News: Advicenne (Euronext: ADVIC), a specialty